News for VTVT Stock

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19 vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer vTv Therapeutics Announces Investment by CinRx Pharma vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update vTv Therapeutics Announces CEO Transition vTv Therapeutics Shares Updated Corporate Presentation vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update vTv Therapeutics Announces Deepa Prasad as New President and CEO vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737 vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399 vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes Aditum Bio Announces Formation of Third Company, Anteris Bio vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientific vTv Therapeutics Announces 2020 First Quarter Financial Results and Update vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format